The Developmental Research Program has been one of the most valuable and productive of the SPORE components. The development of innovative translational research concepts in ovarian cancer is critically dependent on the availability of flexible funding for pilot projects. The purpose of the SPORE Developmental Research Program is to encourage and develop research projects with translational potential that will reduce ovarian cancer incidence and mortality or improve survival and quality of life. Both laboratory and clinical research projects are eligible for funding, provided that they are translational in nature. A portion of the SPORE budget ($90,000 in direct costs) is allocated annually to support pilot projects. Funding is limited to $40,000 per year per project. We will provide up to an additional $10,000 from the Ovarian SPORE Institutional Matching funds in order to fund at the $40,000 per project level. At least three projects have been and will continue to be funded annually. Funding was initially f o r i year and was renewable for another year;now applicants will have the option to apply for 2 years of funding at once. Second-year funding of a 2-year proposal will be dependent on the progress made in the first year, and the proposal will compete with new applications for funding. The purpose of the Developmental Research Program is to fund promising projects by investigators of any age whose work may not focus exclusively on ovarian cancer, but who propose innovative translational studies of ovarian cancer that could become full SPORE projects or compete successfully for funding outside of the SPORE. The objectives of the Developmental Research Program are as follows: Publicize the availability of start-up funding for pilot projects in ovarian cancer translational research. Identify projects that are innovative and have significant potential for reducing ovarian cancer incidence and mortality or for improving survival and quality of life. Encourage collaborations among scientists within the SPORE and with scientists outside the SPORE environment. Help potential pilot project investigators define and articulate translational research goals and the steps required to beneficially translate research into application in humans. Select competing research proposals for funding using internal and external reviewers applying specific criteria. Provide developmental funding for investigators in the SPORE institution and scientists at other selected sites. Closely monitor and work with the Developmental Project investigators to assist them in achieving their translational research goals. Administer a flexible program in which pilot projects that demonstrate promise follow one of three courses: a) They will be funded for another year, possibly with additional support if particularty promising;b) They will be elevated to full SPORE projects;or c) Investigators will be encouraged to apply for an R01 or other peer-reviewed research support. Developmental projects that do not reach their potential will be terminated.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
United States
Zip Code
Huang, Yan; Hu, Wei; Huang, Jie et al. (2018) Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. Mol Cancer Ther 17:464-473
Yang, Hailing; Mao, Weiqun; Rodriguez-Aguayo, Cristian et al. (2018) Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability. Clin Cancer Res 24:5072-5084
Rhyasen, Garrett W; Yao, Yi; Zhang, Jingwen et al. (2018) BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors. PLoS One 13:e0200826
Chen, Jian; Zaidi, Sobia; Rao, Shuyun et al. (2018) Analysis of Genomes and Transcriptomes of Hepatocellular Carcinomas Identifies Mutations and Gene Expression Changes in the Transforming Growth Factor-? Pathway. Gastroenterology 154:195-210
Sun, Chaoyang; Yin, Jun; Fang, Yong et al. (2018) BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. Cancer Cell 33:401-416.e8
Hu, Xiaowen; Sood, Anil K; Dang, Chi V et al. (2018) The role of long noncoding RNAs in cancer: the dark matter matters. Curr Opin Genet Dev 48:8-15
Jung, Youn-Sang; Wang, Wenqi; Jun, Sohee et al. (2018) Deregulation of CRAD-controlled cytoskeleton initiates mucinous colorectal cancer via ?-catenin. Nat Cell Biol 20:1303-1314
Jung, Youn-Sang; Jun, Sohee; Kim, Moon Jong et al. (2018) TMEM9 promotes intestinal tumorigenesis through vacuolar-ATPase-activated Wnt/?-catenin signalling. Nat Cell Biol 20:1421-1433
Nagaraja, Archana S; Dood, Robert L; Armaiz-Pena, Guillermo et al. (2018) Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight 3:
Seo, Hyeonglim; Choi, Ikjang; Whiting, Nicholas et al. (2018) Hyperpolarized Porous Silicon Nanoparticles: Potential Theragnostic Material for 29 Si Magnetic Resonance Imaging. Chemphyschem 19:2143-2147

Showing the most recent 10 out of 648 publications